These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 17261530)

  • 1. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies.
    Pierangeli SS; Vega-Ostertag ME; Raschi E; Liu X; Romay-Penabad Z; De Micheli V; Galli M; Moia M; Tincani A; Borghi MO; Nguyen-Oghalai T; Meroni PL
    Ann Rheum Dis; 2007 Oct; 66(10):1327-33. PubMed ID: 17261530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4.
    Laplante P; Fuentes R; Salem D; Subang R; Gillis MA; Hachem A; Farhat N; Qureshi ST; Fletcher CA; Roubey RA; Merhi Y; Thorin É; Levine JS; Mackman N; Rauch J
    Lupus; 2016 Feb; 25(2):162-76. PubMed ID: 26391610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome.
    Xie H; Kong X; Zhou H; Xie Y; Sheng L; Wang T; Xia L; Yan J
    Clin Immunol; 2015 Oct; 160(2):198-210. PubMed ID: 26065621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.
    Carrera-Marín A; Romay-Penabad Z; Papalardo E; Reyes-Maldonado E; García-Latorre E; Vargas G; Shilagard T; Pierangeli S
    Lupus; 2012 Dec; 21(14):1497-505. PubMed ID: 22933620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.
    Pierangeli SS; Harris EN
    Lupus; 2003; 12(7):539-45. PubMed ID: 12892395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis.
    Raschi E; Chighizola CB; Grossi C; Ronda N; Gatti R; Meroni PL; Borghi MO
    J Autoimmun; 2014 Dec; 55():42-50. PubMed ID: 24685231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies.
    Montiel-Manzano G; Romay-Penabad Z; Papalardo de Martínez E; Meillon-García LA; García-Latorre E; Reyes-Maldonado E; Pierangeli SS
    Ann N Y Acad Sci; 2007 Jun; 1108():540-53. PubMed ID: 17894019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.
    Yalavarthi S; Gould TJ; Rao AN; Mazza LF; Morris AE; Núñez-Álvarez C; Hernández-Ramírez D; Bockenstedt PL; Liaw PC; Cabral AR; Knight JS
    Arthritis Rheumatol; 2015 Nov; 67(11):2990-3003. PubMed ID: 26097119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice.
    Manukyan D; Müller-Calleja N; Jäckel S; Luchmann K; Mönnikes R; Kiouptsi K; Reinhardt C; Jurk K; Walter U; Lackner KJ
    J Thromb Haemost; 2016 May; 14(5):1011-20. PubMed ID: 26786324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.
    Ferrara DE; Liu X; Espinola RG; Meroni PL; Abukhalaf I; Harris EN; Pierangeli SS
    Arthritis Rheum; 2003 Nov; 48(11):3272-9. PubMed ID: 14613293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome.
    Djokovic A; Stojanovich L; Kontic M; Stanisavljevic N; Radovanovic S; Marisavljevic D
    Isr Med Assoc J; 2014 Mar; 16(3):162-7. PubMed ID: 24761704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.
    Pierangeli SS; Espinola RG; Liu X; Harris EN
    Circ Res; 2001 Feb; 88(2):245-50. PubMed ID: 11157679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.
    Pierangeli SS; Colden-Stanfield M; Liu X; Barker JH; Anderson GL; Harris EN
    Circulation; 1999 Apr; 99(15):1997-2002. PubMed ID: 10209004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome.
    Müller-Calleja N; Köhler A; Siebald B; Canisius A; Orning C; Radsak M; Stein P; Mönnikes R; Lackner KJ
    Thromb Haemost; 2015 May; 113(5):1071-83. PubMed ID: 25589411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome.
    Benhamou Y; Bellien J; Armengol G; Brakenhielm E; Adriouch S; Iacob M; Remy-Jouet I; Le Cam-Duchez V; Monteil C; Renet S; Jouen F; Drouot L; Menard JF; Borg JY; Thuillez C; Boyer O; Levesque H; Richard V; Joannidès R
    Arthritis Rheumatol; 2014 Nov; 66(11):3210-20. PubMed ID: 25047402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis.
    Pericleous C; Ruiz-Limón P; Romay-Penabad Z; Marín AC; Garza-Garcia A; Murfitt L; Driscoll PC; Latchman DS; Isenberg DA; Giles I; Ioannou Y; Rahman A; Pierangeli SS
    Rheumatology (Oxford); 2015 Apr; 54(4):722-7. PubMed ID: 25273993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.